The Looksmaxxing Economy
scott belsky
@scottbelsky
· 3
−2.7%
since Aug 4
The idea
I believe cosmetic enhancement is going mainstream for both sexes, and that GLP-1 weight loss is quietly feeding a new wave of demand for skin tightening and facial fillers. I own the whole stack: injectables as the recurring-revenue core, devices and implants for the medspa buildout, GLP-1 makers as the accelerant, and consumer platforms for the demographic shift. It's moderately concentrated, large caps for ballast with smaller, higher-beta names sized as asymmetric bets, and I keep a cash buffer on the side.
What it owns
- Telehealth and beauty platforms serve as the entry point where mainstream consumers, especially men and younger demographics, first access enhancement services. · Hims & Hers HealthIt is the mainstream telehealth front door for men's aesthetic access, including hair loss, skin, hormones, and weight-loss medications without clinic stigma., Oddity TechIt monetizes personalization and diagnostics for routine aesthetic maintenance through AI-driven tools and direct-to-consumer beauty brands., e.l.f. BeautyIt captures the mass-market tailwind of beauty becoming a daily habit for the youngest demographic across the take., Ulta BeautyIt is the physical retail gateway where normalized beauty and grooming spending across all demographics appears in sales and traffic., Estée LauderIt is a depressed prestige-skincare name riding the same secular beauty demand, with turnaround and geographic recovery optionality., LifeMDIt operates a small-cap telehealth platform for weight-loss and men's health access, widening the pipeline of patients who become aesthetics consumers., Beauty Health CompanyIts Hydrafacial is the repeatable consumable workhorse in the medspa channel that this take identifies as expanding, though the turnaround depends on stabilizing equipment sales and growing consumables usage.30%
- Medspas and surgical centers require continuous capital investment in machines and implants, creating operating leverage as aesthetic capacity expands across the market. · Align TechnologyInvisalign serves as an established gateway aesthetic procedure, often the first cosmetic spending moment for both men and adults., InModeIt sells radiofrequency skin-tightening and body-contouring platforms that medspas deploy to serve post-weight-loss loose-skin demand with high margins., Establishment LabsIts Motiva implants are the premium, safety-differentiated play on body procedures as stigma fades, including planned US market entry., Envista HoldingsIt supplies orthodontics, implants, and dental aesthetics equipment, offering diversified exposure to smile enhancement as routine maintenance., Apyx MedicalIts Renuvion helium plasma technology directly targets skin contraction after massive weight loss, the purest play on the GLP-1-to-body-contouring pipeline.23%
- Rapid weight loss reshapes faces and bodies, driving demand for tightening, filling, and contouring procedures across the aesthetic economy. · Eli LillyIts Zepbound and Mounjaro create a pipeline of newly-thin patients seeking fillers, tightening, and contouring across the aesthetic stack., Novo NordiskIts Ozempic and Wegovy drive facial volume loss that funnels patients into injectables and other enhancement procedures.17%
- Botox and fillers require repeat treatments every few months, creating predictable recurring revenue streams that form the foundation of the aesthetics economy. · AbbVieIt owns Botox and Juvederm, the default brands in the recurring injectable and filler core of aesthetic medicine., EvolusIts Jeuveau toxin targets younger, first-time injectable patients, the fastest-expanding cohort as enhancement becomes normalized.15%
- Distributors and specialty suppliers capture revenue based on procedure volume, independent of which brand or clinic wins share. · Henry ScheinIt supplies the dental and medical practices that expand as aesthetic procedures become routine, providing picks-and-shovels exposure to procedure growth.5%
- Cash10%